Owlstone Medical and Cancer Research UK (CRUK) have begun a clinical trial designed to identify biomarkers of cancer in breath samples. The goal is to find volatile organic compounds (VOCs) that indicate the presence of cancer, enabling physicians to make quick, noninvasive diagnoses.
Emmaus Medical recently received FDA (The U.S. Food and Drug Administration) approval for sickle cell disease therapy Endari (L-gluitamine), ending two decades of drought for treatment of the disease and giving an alternative to the only other drug on the market, hydroxyurea.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.